Statin and Aspirin for Chemoprevention of Hepatocellular Carcinoma: Time to Use or Wait Further?

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2022 Jan 13

PMID 35021597

Authors

Myung Ji Goh

Dong Hyun Sinn

Affiliations

Soon will be listed here.

Abstract

Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention of hepatocellular carcinoma (HCC). However, observational data is prone to bias, and no prospective randomized trials are currently available to assess the risks and benefits of statin or aspirin therapy for chemoprevention of HCC. It is therefore important for clinicians and researchers to be aware of the quality of current evidence regarding this issue. In this review, we summarize currently available evidence to assist clinicians with their decision to use statin or aspirin and provide information for further clinical investigations.

Citing Articles

Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.

Wang J, Qiu K, Zhou S, Gan Y, Jiang K, Wang D Ann Med. 2025; 57(1):2455539.

PMID: 39834076 PMC: 11753015. DOI: 10.1080/07853890.2025.2455539.

Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks.

Elshaer A, Lizaola-Mayo B Life (Basel). 2025; 14(12.

PMID: 39768407 PMC: 11679757. DOI: 10.3390/life14121701.

Statin Monotherapy Not Inferior to Aspirin or Combined Aspirin and Statins Reducing the Incidences of Cirrhosis, HCC, and Mortality in MAFLD/MASH Patients: A Population Cohort Study.

Lee C, Huang Y, Hsu T, Yen T, Hsieh S Int J Gen Med. 2025; 17:6495-6511.

PMID: 39742030 PMC: 11687094. DOI: 10.2147/IJGM.S481724.

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on "Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients....

Huang C, Yeh M, Dai C, Huang J, Chuang W, Yu M Clin Mol Hepatol. 2024; 31(1):e64-e66.

PMID: 39159946 PMC: 11791571. DOI: 10.3350/cmh.2024.0638.

Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on "Statin and aspirin for chemoprevention of hepatocellular....

Yiu D, Lin H, Wong V, Wong G, Liu K, Yip T Clin Mol Hepatol. 2024; 30(4):970-973.

PMID: 38964740 PMC: 11540373. DOI: 10.3350/cmh.2024.0280.

References

Rothwell P, Price J, Fowkes F, Zanchetti A, Roncaglioni M, Tognoni G . Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379(9826):1602-12. DOI: 10.1016/S0140-6736(11)61720-0. View

Zhong G, Liu Y, Ye Y, Hao F, Wang K, Gong J . Meta-analysis of studies using statins as a reducer for primary liver cancer risk. Sci Rep. 2016; 6:26256. PMC: 4873806. DOI: 10.1038/srep26256. View

Bader T, Korba B . Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res. 2010; 86(3):241-5. PMC: 2869246. DOI: 10.1016/j.antiviral.2010.02.325. View

Shen Y, Risch H, Lu L, Ma X, Irwin M, Lim J . Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. Cancer Causes Control. 2020; 31(4):321-332. PMC: 7136513. DOI: 10.1007/s10552-020-01277-1. View

Menter D, Ramsauer V, Harirforoosh S, Chakraborty K, Yang P, Hsi L . Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One. 2012; 6(12):e28813. PMC: 3245236. DOI: 10.1371/journal.pone.0028813. View

Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J . Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2009; 14(5):1180-93. PMC: 3822754. DOI: 10.1111/j.1582-4934.2009.00771.x. View

Blais P, Lin M, Kramer J, El-Serag H, Kanwal F . Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. Dig Dis Sci. 2015; 61(6):1714-20. DOI: 10.1007/s10620-015-4000-6. View

German M, Lutz M, Pickhardt P, Bruce R, Said A . Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study. J Clin Gastroenterol. 2019; 54(8):733-740. DOI: 10.1097/MCG.0000000000001260. View

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

10.

Uschner F, Ranabhat G, Choi S, Granzow M, Klein S, Schierwagen R . Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 2015; 5:14573. PMC: 4585958. DOI: 10.1038/srep14573. View

11.

Ward N, Watts G, Eckel R . Statin Toxicity. Circ Res. 2019; 124(2):328-350. DOI: 10.1161/CIRCRESAHA.118.312782. View

12.

Wong Y, Qiu T, Ng G, Zheng Q, Teo E . Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis. J Clin Gastroenterol. 2021; 55(7):615-623. DOI: 10.1097/MCG.0000000000001478. View

13.

Lee T, Wu J, Yu S, Lin J, Wu M, Wu C . The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer. 2017; 141(7):1307-1314. DOI: 10.1002/ijc.30784. View

14.

Emberson J, Kearney P, Blackwell L, Newman C, Reith C, Bhala N . Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012; 7(1):e29849. PMC: 3261846. DOI: 10.1371/journal.pone.0029849. View

15.

Jeong G, Lee K, Kim J, Eisenhut M, Kronbichler A, van der Vliet H . Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(6). PMC: 6617015. DOI: 10.3390/jcm8060819. View

16.

Yi C, Song Z, Wan M, Chen Y, Cheng X . Statins intake and risk of liver cancer: A dose-response meta analysis of prospective cohort studies. Medicine (Baltimore). 2017; 96(27):e7435. PMC: 5502182. DOI: 10.1097/MD.0000000000007435. View

17.

Tran K, McMenamin U, Coleman H, Cardwell C, Murchie P, Iversen L . Statin use and risk of liver cancer: Evidence from two population-based studies. Int J Cancer. 2019; 146(5):1250-1260. DOI: 10.1002/ijc.32426. View

18.

Kim G, Kang E . Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms. Semin Liver Dis. 2019; 39(2):141-152. DOI: 10.1055/s-0039-1679956. View

19.

Chang Y, Liu Q, Zhou Z, Ding Y, Yang M, Xu W . Can Statin Treatment Reduce the Risk of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis. Technol Cancer Res Treat. 2020; 19:1533033820934881. PMC: 7307281. DOI: 10.1177/1533033820934881. View

20.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View